Antibacterial activity of Mn(i) and Re(i) tricarbonyl complexes conjugated to a bile acid carrier molecule by Betts, J.W. et al.
This is a repository copy of Antibacterial activity of Mn(i) and Re(i) tricarbonyl complexes 
conjugated to a bile acid carrier molecule.




Betts, J.W., Roth, P., Pattrick, C.A. et al. (4 more authors) (2020) Antibacterial activity of 
Mn(i) and Re(i) tricarbonyl complexes conjugated to a bile acid carrier molecule. 
Metallomics, 12 (10). pp. 1563-1575. ISSN 1756-5901 
https://doi.org/10.1039/d0mt00142b
This is a pre-copyedited, author-produced version of an article accepted for publication in 
Metallomics following peer review. The version of record [ Jono W Betts, Patrick Roth, 
Calum A Pattrick, Hannah M Southam, Roberto M La Ragione, Robert K Poole, Ulrich 
Schatzschneider, Antibacterial activity of Mn(I) and Re(I) tricarbonyl complexes conjugated
to a bile acid carrier molecule, Metallomics, Volume 12, Issue 10, October 2020, Pages 




Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 






Antibacterial activity of Mn(I) and Re(I) tricarbonyl complexes conjugated 




Jono W. Betts,a Patrick Roth,b Calum A. Pattrick,c Hannah Southam,c Roberto La Ragione,a 
Robert K. Poole,c and Ulrich Schatzschneiderb*  
 
a Department of Pathology and Infectious Diseases, School of Veterinary Medicine, 
University of Surrey, Guildford, United Kingdom 
b Institut für Anorganische Chemie, Julius-Maximilians-Universität Würzburg, Am Hubland, 
D-97074 Würzburg, Germany 







* Corresponding author: eMail: ulrich.schatzschneider@uni-wuerzburg.de; 




A bifunctional cholic acid-bis(2-pyridylmethyl)amine (bpa) ligand featuring an amide linker 
was coordinated to a manganese(I) or rhenium(I) tricarbonyl moiety to give 
[M(bpacholamide)(CO)3] with M = Mn, Re in good yield and very high purity. Strong antibacterial 
activity was observed against four strains of methicillin-susceptible (MSSA) and methicillin-
resistant (MRSA) Staphylococcus aureus, with minimum inhibitory concentrations (MICs) in 
the range of 2–3.5 µM. No difference in response was observed for the MSSA vs. MRSA 
strains. Activity was also independent of the nature of the metal center, as the Mn and Re 
complexes showed essentially identical MIC values. In contrast to some other metal carbonyl 
complexes, the activity seems to be unrelated to the release of carbon monoxide, as 
photoactivation of the Mn complex reduced the potency by a factor of 2–8. Both metal 
complexes were non-toxic in Galleria mellonella larvae at concentrations of up to 100× the 
MIC value. In vivo testing of Galleria larvae infected with MRSA/MSSA demonstrated a 
significant increase in overall survival rates from 46% in the control to 88% in the group treated 
with the metal complexes. ICP-MS analysis showed that the Mn and Re cholamide complexes 
are efficiently internalized by E. coli cells and do not interfere with membrane integrity, as 
evident from a lack of release of intracellular ATP. An increased sensitivity was observed in 
acrB, acrD, and mdt mutants that are defective in multidrug exporters, indicating that the 
compounds have an intracellular mechanism of action. Furthermore, E. coli mntP mutants, 
defective in the gene encoding an Mn exporter, were  more sensitive than the wildtype, while 
inactivation of the regulator that controls expression of the Mn uptake proteins MntP and MntH  
slightly increased sensitivity to the compound. Single knockout mutants defective in genes 
linked to bile salt and oxidative stress response (dinF, yiaH, sodA, katE, and soxS) did not show 
increased sensitivity relative to the wild type. Overall, neither the cholic acid moiety nor the 
metal-carbonyl fragment alone appear to be responsible for the biological activity observed 




For many decades, bacterial infections were well-controlled by antimicrobial drugs based on a 
wide range of structural motifs. However, inappropriate and overuse together with the slow 
appearance of new antibiotics on the market due to a lack of development activity by the 
pharmaceutical industry have led to the emergence of an antimicrobial resistance (AMR) 
crisis,1-3 as more and more bacterial strains become non-responsive to standard drugs and 
sometimes even drugs of last resort. In this serious situation, no part of the chemical space 
should be left unexplored for potential new drug candidates with novel mechanisms of action 
that cannot be evaded by bacterial resistance processes. In that context, (organo)metal 
compounds are a promsing source for new antibacterial drugs4, 5 and contrary to common 
believe, can be subject to standard drug development procedures and optimization of ADMET 
properties. 
Some recent large-scale nonbiased screening efforts have revealed a surprisingly high hit rate 
for metal-based antibacterial agents (approx. 10% of more than 900 compounds tested), which 
was even higher than that for purely organic compounds submitted to the same assays. 
Minimum inhibitory concentrations (MICs) down to the nanomolar range were observed on 
methicillin-resistant Staphylococcus aureus (MRSA).5 Many of the tested compounds feature 
very elaborate co-ligands on the metal center and some are coordinated to established drugs, 
such as azole antimicrobials.6 Conversely, much less is known about the antibacterial activity 
of (organo)metal fragments conjugated to biological carrier molecules. Promising results have 
been obtained with the systematic optimization of metallocenes attached to antimicrobial 
peptides (AMPs), which lead to identification of conjugates with low micromolar MIC values 
(5–10 µM).7 Still, there is very little work on other bio-derived carrier groups for metal-based 
antibacterial drug candidates. 
Interestingly, for about two decades, cholic acid derivatives have been explored as potential 
mimics of squalamine and polymyxin B antibiotics (Chart 1),8-10 although studies of the 
biological activity of cholane and norcholane derivatives date back to the 1950s.11 As many of 
these compounds carry charged or at least highly polar functional groups,12-14 we became 
interested in the functionalization of such cholic acid-related carrier molecules with cationic 





















































polymyxin B1: R = CH3
polymyxin B2: R = H
 
Chart 1. Structure of some cholic acid derivatives explored for antibiotic activity comparable 
to that of polymyxin B1 and B2. 
A number of such compounds based on technetium(V) and gadolinium(III) have been 
evaluated for use as contrast agents in radioimaging16, 17 and magnetic resonance imaging 
(MRI).18 However, Shen and coworkers also reported on the antibacterial and antifungal 
activity of a bifunctional bile acid-bpa conjugate, although no metal complexes of this ligand 
were prepared.19 Based on our own experience with tridentate bis(2-pyridiylmethyl)amine 
(bpa) ligands,20, 21 which easily bind to a wide range of transition metals in either a square-
planar or facial octahedral coordination mode, manganese(I) and rhenium(I) tricarbonyl 
complexes of such a bifunctional chelator-cholic acid conjugate appeared to be an interesting 
synthetic target. 
Results and Discussion 
Synthesis and characterization 
For facile bioconjugation to the cholic acid carrier molecule, which is easily commercially 
available, a ligand with a pendant aminoalkyl linker was required as the coupling partner. 
Although we have also explored tris(pyrazolyl)methane (tpm)22-25 and bis(pyrazolyl)-
ethylamine (bpea)26, 27 ligands in the past, based on the promising antibacterial activity of 
manganese tricarbonyl complexes with bis(2-pyridylmethyl)amine (bpa) chelators and their 
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tetradentate tpa analogues,20, 21, 28-30 a bpa ligand with a 2-aminoalkyl group as the "third arm" 
on the central tertiary amino group was selected. Although N,N-bis(2-pyridylmethyl)ethan-1,2-
diamine (bpen) 4 is accessible by a variety of synthetic methods,31-33 the compound turned out 
to be prone to decomposition in our hands and therefore, a direct route to a protected bpen 
derivative was explored, from which 4 was to be released and then directly used in the next 
step. In contast to Boc-protected 1,2-ethylenediamine (en) serving as a key building block, for 
example in the syntheses reported by Nagano32 and Finney,33 our approach is based on acetyl-
protected bpen 3, as this ligand could also serve as a non-targeted control. Therefore, 2-methyl-
4,5-dihydro-1H-imidazole (lysidine) 2 was heated to 75 °C in water for 2 h to release N-acetyl-
1,2-ethylenediamine.34 Then, two equivalents of 2-(chloromethyl)pyridine hydrochloride 1 
were added and slowly neutralized with an excess of 10 M sodium hydroxide. After further 
heating, extraction, and purification through a short alumina column, N-acetyl-protected bpen 
3 was isolated in analytically pure form on close to a 10 g scale as a beige solid in decent yield 
and suitable for long-term storage (Scheme 1 top).35 The acetyl protective group was removed 
by reflux in concentrated hydrochloric acid for 24 h and free bpen 4 obtained in near-
quantitative yield as a pale yellow oil. Since the compound is prone to decomposition, it was 
directly conjugated to cholic acid 5 in tetrahydrofuran with N,N'-dicyclohexylcarbodiimide 
(DCC) and N-hydroxysuccinimide (NHS) as the coupling agents and N,N-
diisopropylethylamine (DIPEA) as base (Scheme 1 center). After column chromatography on 
silica using a mixture of dichloromethane and methanol (5:1 v/v) as the eluent, the bifunctional 
cholic acid-bpa ligand 6 was obtained in good yield on a gram scale in analytically pure form. 
The successful coupling is evident in the 1H and 13C NMR spectrum of 6 from the amide group 
signal at 7.77 and 172.43 ppm, respectively. Furthermore, the two peaks of the ethylene linker 
also show notable shift differences between 4 and 6. In particular, the triplet of the distal 
methylene group – the one adjacent to the amide nitrogen atom – moves from 2.63 ppm in 4 to 
3.19 ppm in 6, while the signal of the proximal methylene protons next to the bpa moiety only 
shifts by 0.04 ppm to lower field. The 13C NMR spectrum is also indicative of the successful 
coupling, as the two ethylene linker peaks move from 57.23 and 39.40 ppm in 4 to 53.17 and 
36.62 ppm in 6, respectively, for the proximal and distal carbon atoms. Remarkably, in the 125 
MHz 13C NMR of conjugate 6, all 32 independent signals for the cholic acid and bpa moieties 
as well as the linker could be clearly detected and assigned with the aid of HSQC and HMBC. 
Other literature procedures for the synthesis of 6 used the reductive amination of N-2-
(aminoethyl)cholamide with 2-pyridine carboxaldehyde and sodium triacetoxyborohydride in 
higher overall yield,13, 19 but we prefer the DCC/NHS-mediated coupling of 4 and 5 as shown 
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in Scheme 1, as it also allowed conjugation of the bpa building block to other carboxylate-













3: R = COCH3
 (50%)
4: R = H (96%)
1 2
conc. HCl
130 °C, 24 h
cholic acid 5


















, reflux, 3 h or
[ReBr(CO)5] 8
toluene, reflux, 3 h
9: M = Mn (76%)




















Scheme 1. Synthesis of metal tricarbonyl complexes 9 and 10 by reaction of cholic acid-
conjugated bis(2-pyridylmethyl)amine (bpa) ligand 6 with manganese(I) or rhenium(I) 
pentacarbonyl bromide 7 or 8 at reflux in dichloromethane or toluene. The central amide 
coupling step uses N,N'-dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide (NHS) 
as the activating agents and N,N-diisopropylethylamine (DIPEA) as base. 
 
The metal tricarbonyl complexes were then easily prepared by reflux with metal pentacarbonyl 
bromides 7 or 8. While the synthesis of manganese compound 9 was carried out in 
dichloromethane, the preparation of the rhenium analogue 10 required use of higher boiling 









simply washed away with proper solvent to obtain Mn complex 9 as a yellow powder in 76% 
yield, while the Re congener 10 was isolated as a colorless solid in a somewhat lower yield of 
41%  (Scheme 1 bottom). In both cases, elemental analysis required the inclusion of some water 
of solvation, which is not surprising given the number of polar groups in the title compounds. 
ESI mass spectrometry showed the [M-Br]+ species as the only notable peak in the whole 
measured range (see Fig. 1 and Supporting Information). 
 
Figure 1. The ESI mass spectrum of manganese tricarbonyl complex 9 in methanol shows 
only the signal of the [M-Br]+ species with an excellent match of the isotope pattern. The 
difference between experimental and calculated exact mass is -0.005 Da. 
 
Most of the 1H and 13C NMR signal exhibit only very minor shifts upon metal coordination, 
but there are some notable differences in the peaks assigned to the bpa moiety, which are 
fortunately clearly distinct from the complicated and often overlapping cholic acid signals. 
Most diagnostic of metal coordination in bpa complexes is the splitting of the methylene group 
signal, which appears as a singlet with an intensity of 4H at 3.76 ppm in free ligand 4, but gives 
rise to two geminal doublets at 4.88 and 4.71 ppm in 9 vs. 5.04 and 4.95 ppm in 10, with 2J 
coupling constants of 17 Hz. Some downfield shift is also evident for the pyridine H6 protons 
in proximity to the ring nitrogen atoms, which move from 8.46 ppm in 4 to 8.87 and 8.80 ppm 
in 9 and 10, respectively. The methylene 13C signals move from 59.59 ppm in the free ligand 
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carbonyl signals were detected in the expected 2:1 ratio for the Mn compound at 218.90 and 
218.35 ppm and for the Re complex at 196.38 and 195.16 ppm. The amide proton peak also 
experiences a notable downfield shift, as it appears as a triplet at 7.77 ppm in free ligand 4, but 
moves to 8.10 ppm in 9 and 10. As the ligand and metal complex 1H NMR spectra were 
recorded in the same solvent (DMSO-d6), this might be indicative of an interaction of the amide 
NH with the metal carbonyl groups. 
 
Biological activity 
Strong antibacterial activity for the two [M(bpencholamide)(CO)3]Br complexes 9 and 10 was 
observed against all four tested strains of methicillin-susceptible (MSSA) vs. methicillin-
resistant (MRSA) Staphylococcus aureus, with minimum inhibitory concentrations (MICs) in 
the range of 2.3–3.1 µM for 9 (M = Mn) and 2–3.4 µM for 10 (M = Re), respectively 
(Table 1 top). No relevant differences in response were observed for the methicillin-susceptible 
vs. methicillin-resistant strains. Exchange of the metal center from Mn to Re also did not 
significantly influence the MIC values. The activity of both complexes is comparable to 
antibiotics currently licensed for S. aureus, such as amikacin, where wild type MIC 
distributions range between 1 and 30 µM. [The European Committee on Antimicrobial 
Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. 
Version 10.0, 2020. http://www.eucast.org. -> That's another "grey" literature - we need "real" 
citations] In a recent study screening 906 metal complexes, including those of Mn, Cu, Ru and 
Ag, 246 compounds showed MICs equal or lower than 10 µM against one or more pathogens. 
However, MIC values reported for Mn complexes in that study were between 5 and 175 µM 
against S. aureus. Thus, complexes 9 and 10 have greater antibacterial activity than any of the 
Mn complexes reported.5 
As metal carbonyl complexes have been widely explored as CO-releasing molecules (CORMs) 
with a potential light-triggered release of carbon monoxide,36, 37 the effect of illumination on 
the biological activity was also studied. MIC values of the rhenium compound 10 were not 
affected at all by exposure to UV light (Table 1 center), in line with the general photostability 
of Re(CO)3 complexes. In the case of the manganese complex 9, differences between 
illuminated vs. non-illuminated samples were only observed for the highly responsive bacterial 
strains and photoactivation generally reduced the potency by a factor of 2–8, indicating that it 
is the intact metal tricarbonyl moiety which is relevant for the antibacterial activity. Some small 
deviations between the MSSA vs. MRSA and photoactivation MIC values are possibly due to 





laboratories. [US: Previous sentence sufficient as an explanation?!? JB: We need to decide 
which values to proceed with here. I don’t believe the addition of both our results is wise as 
our values are slightly different (mine are mean values). Although the data showing the 
comparison of +/- UV is very useful, all my further work (time-kills and Galleria assays) are 
based on my MICs. I also have MICs for strains of Streptococci, Acinetobacter, Pseudomonas 
and Enterococci] Other bacterial strains, including MG1655 as a common wildtype E. coli 
strain, EC958 as an example of uropathogenic E. coli, and AB184 and AB210 as clinically 
isolated multidrug-resistant A. baumannii strains, were also tested, but generally not very 
responsive towards both compounds (Table 1 bottom). The Re complex seems to be somewhat 
more active, but MIC values were high, with the most responsive AB184 showing a MIC of 
32 µM.  
 
 
Figure 2. Antimicrobial effect of 9 (at a sub-MIC level) against wildtype BW25113 E. coli, 
with (purple line) and without (red line) UV light exposure at ___ nm for ___ min. Black and 
blue lines indicate treatment with 1% DMSO as a control with and without UV photoactivation, 
respectively. All data points are the mean of at least three biological replicates, with errors bars 
representing the standard deviation.  
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Table 1. Mean minimum inhibitory concentration (MIC) of [M(bpencholamide)(CO)3]Br 9 (M = 
Mn) and 10 (M = Re) vs. strains of methicillin-resistant S. aureus (MRSA) and methicillin-
susceptible S. aureus (MSSA) as well as strains of E. coli (MG1655, EC958) and A. baumannii 
(AB184, AB210). UV +/- indicates illumination (or not) of samples at 365 nm for 6 min. 
Strain UV 
Mean minimum inhibitory concentrations of 
[M(bpencholamide)(CO)3]Br (in µM) 
9 (M = Mn) 10 (M = Re) 
MSSA NCTC 12981 - 3.1 3.4 
MSSA SH1000 - 2.3 2.7 
MRSA NCTC 12493 - 2.3 2.7 
MRSA USA300 - 2.3 2.0 
 
SH1000 
- 4 4 
+ 32 4 
USA300 
- 8 4 
+ 16 4 
 
MG1655 
- >1024 1024 
+ >1024 1024 
EC958 
- >1024 256 
+ >1024 256 
AB210 
- 256 64 
+ 256 64 
AB184 
- 64 32 
+ 128 32 
 
The effect of UV light exposure on bacterial cell growth as determined by optical density at 
595 nm was also studied in a time-dependent manner in the presence and absence of Mn 
compound 9. Illumination of 1% DMSO added to the cell culture, as required to solubilize the 
metal complexes, did not significantly affect bacterial growth (Fig. 2, dashed blue vs. solid 
black line). The addition of 400 µM of complex 9 with UV photoactivation led to some initial 




experiment, but then the bacteria started to grow and reached final OD levels comparable to 
the 1% DMSO controls (Fig. 2, solid violet line). The same concentration of metal complex in 
the absence of UV light resulted in a much longer inhibition of bacterial growth and final OD 
levels reached only about half of the maximum values observed for the other conditions, after 
800 min of growth (Fig. 2, dashed red line). 
Kill-kinetic assays indicate that Mn complex 9 is bactericidal against all four MRSA/MSSA 
strains tested, with >5 log lower bacterial numbers compared to the no drug control at 24 h and 
>2 log reduction in bacterial numbers when compared to the starting inocula (Fig. 3a-d). The 
rhenium analogue 10 showed bacteriostatic activity against three of the four strains (Fig. 3a, b 
and d). Although bacterial numbers initially reduce, after 24 h they recover to approximately 
that of the starting inocula. However, against MRSA NCTC 12493, complex 10 was 
bactericidal, with bacterial numbers reducing >3 log vs. the starting inoculum and >6 log 
reduction when compared to the no treatment control. 
 
Figure 3. Kill-kinetics of [M(bpencholamide)(CO)3]Br 9 (M = Mn) and 10 (M = Re) against 
methicillin-susceptible S. aureus strains a) NCTC 12981, b) SH1000 and methicillin-resistant 
S. aureus strains c) NCTC 12493 and d) USA300; MH2 control: Mueller-Hinton 2 (MH2) 
cation-adjusted broth. 
 
Both metal complexes 9 and 10 were non-toxic on Galleria mellonella at concentrations up to 
100 times greater than those required for bacterial killing (Fig. 4). In vivo testing of larvae 
infected with MRSA/MSSA showed that treatment with [Mn(bpencholamide)(CO)3]Br 9 
significantly increased survival compared to the PBS control (p ≤ 0.028 for MSSA and p ≤ 
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0.011 for MRSA), with overall survival rates of 88% (±7.98 percentage points [pp]) versus 
46% (±10.95 pp) in the control group (Fig. 5). 
 
Figure 4. Precent survival of G. mellonella larvae upon exposure to [M(bpencholamide)(CO)3]Br 
9 (M = Mn) at 100× MIC (red trace) compared to S. aureus NCTC 12981 (green trace). 
Treatment of the larvae with phosphate buffered saline (PBS), complex 9 at 10× MIC and 
complex 10 (M = Re) at 10× and 100× MIC gave survival curves identical to the red trace (data 
not shown for clarity). 
 
Figure 5. Survival curves for G. mellonella larvae infected with methicillin-susceptible 
S. aureus strains a) NCTC 12981, b) SH1000 and methicillin-resistant S. aureus strains c) 
NCTC 12493 and d) USA300 via left proleg injection, followed by right proleg injection of 
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Assessment of membrane damage based on extracellular ATP levels 
Previous work showed that some manganese(I) tricarbonyl complexes with antibacterial 
properties elicited membrane disruption, as evident from a detectable increase in the release of 
ATP.38 As the Mn and Re cholate conjugates 9 and 10 presented in this paper feature the same 
M(bpa)(CO)3 moiety, a similar approach was used to determine whether they also induce 
membrane disruption that could be involved in the mechanism of antibacterial action. Gram-
negative (A. baumannii AB184) and Gram-positive (S. aureus SH1000) bacterial cultures were 
treated with 9 and 10 at sub-MIC concentrations and extracellular ATP levels were measured 
with a luciferin-based assay. However, in the case of AB184, the amount of ATP released after 
120 min of incubation was even lower than that induced by DMSO applied as a control and in 
the case SH1000, the amount of extracellular ATP also did not correlate with incubation time 
and was generally low (Fig. 6). Thus, in contrast to the previously reported generation of Mn 
tricarbonyl compounds,21 no ATP release was identified in response to treatment. Therefore, 
cellular membrane disruption does not appear to be involved in the mechanism of action of 
these complexes. 
 
Figure 6. Changes in extracellular ATP released from AB184 (panel A) and SH1000 (panel 
B) cells were measured using recombinant luciferase and D-luciferin upon treatment with 9 
(blue line) or 10 (red line) at half-MIC concentrations (32 µM for 9 and 16 µM for 10 with 
AB184; 2 µM for both compounds with SH1000). DMSO at 1% (black line) was used as a 
control. Data points represent the mean of three replicates and errors bars show the standard 
deviation. Standard curves were used to determine ATP content from measured luminescence.  
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Metal analysis by ICP-MS to study intracellular accumulation  
ICP-MS analysis of the intracellular metal content of E. coli cells treated with [Mn(bqpa-
κ3N)(CO)3]Br investigated previously highlighted a significant intracellular accumulation of 
manganese in response to treatment (Fig. S1).21 Therefore, potential accumulation of cholate 
conjugates 9 and 10 was investigated with ICP-MS. The total metal content of Mn and Re in 
bacterial cells increased with incubation time following treatment with the respective cholate 
conjugate (Fig. 7A). Although this analysis method is unable to discriminate between uptake 
of the fully intact conjugate vs. part of the metal-binding moiety, the data suggests that at least 
part of the compounds enters the cells. 
Therefore, several strains with knockouts in genes encoding for E. coli efflux pumps were 
initially tested against [Mn(bqpa-κ3N)(CO)3]Br serving as a control. OD595 values measured 
after 5 h of incubation for acrB-, acrD-, and mdtF- mutant strains exposed to the metal complex 
were significantly lower than those of wildtype E. coli, while only the emr- mutant showed 
significantly lower growth in the untreated samples compared to the wildtype, indicating that 
knock out of these pumps renders E. coli more sensitive to the manganese compound  
(Fig. S2A). This effect was apparent in the presence and absence of UV light exposure for the 
strains with mutations in the AcrB and AcrD subunits of multidrug efflux pumps known to 
export a wide range of antimicrobial compounds knocked out (Fig. S2C+D). RT-PCR also 
showed that E. coli increased expression of these genes in response to metal complex treatment 
(Fig. S2B). These data reinforce the idea that the compound enters cells and exerts intracellular 
antibacterial activity, with efflux required to attenuate the effect. 
This increased sensitivity of efflux knockout mutants is also observed for 9 and 10 (Fig. 7B+C), 
which is in line with the ICP-MS data suggesting that the complexes act on an intracellular 
target. An E. coli mntP mutant with a knockout in a manganese exporter also showed an 
increased sensitivity to 9, although this effect was apparent only when UV light activation was 
used to release the CO ligands and not with an intact Mn(CO)3 moiety (Fig. 7C). The mntP- 
mutant did not show increased sensitivity to the rhenium analogue 10 with or without UV 
photoactivation. Again, this matches the results obtained for previously studied [Mn(bqpa-
κ3N)(CO)3]Br. The mntP mutant strain of E. coli is more sensitive to the compound than the 
wildtype, while knockout of the regulator that controls expression of mntP and mntH ,which 
are involved in Mn uptake, increased the sensitivity to the compound to smaller degree. 
Furthermore, mutation of mntH had no effect on sensitivity. Expression of mntP (Mn efflux) 
increased and expression of mntH (Mn uptake) decreased in response to treatment with 
15 
 
[Mn(bqpa-κ3N)(CO)3]Br (Fig. S3). Expression of these genes is controlled by the MntR 
regulator that is located in the cytoplasm, further reinforcing the ICP data indicating increased 
intracellular Mn levels.39 However, the molecular mechanism by which the Mn compound 
interacts with the regulator is currently unknown. Both direct binding as well as indirect 
modulation of intracellular Mn levels might lead to the effects observed. 
In summary, the intact compounds, or at least some metal-containing fragment of them, 
accumulate inside the cell. The increased sensitivity of E. coli strains with a perturbed efflux 
due to gene knockout indicate that the compounds have an intracellular mechanism of action. 
AcrB and AcrD may not be responsible for, and capable of, carrying the compounds out of the 
cells, as the increased sensitivity may also be a result of alternative effects caused by the 
knockout of the genes encoding these efflux pump subunits. 
 
Figure 7. A) ICP-MS analysis of change in intracellular Mn and Re in E. coli cells treated with 
9 and 10. The level of rhenium at t = 0 was below the detection limit and thus is given as 0 for 
data display purposes only. B+C) Growth curves of E. coli mutants with the transporter genes 
acrB and acrD knocked out upon exposure to 9 (B) and 10 (C) in the absence of UV activation. 
D–F) Growth curves of mntP- E. coli relative to wildtype in response to 9 without (D) and with 
(E) UV photoactivation as well as 10 kept in the dark (F). All data points are the mean of three 
biological replicates with errors bars representing standard deviation. 
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Response of stress-sensitive mutants 
In order to investigate the role of the cholate moiety, the sensitivity of E. coli single knockout 
mutants (from the Keio collection) with mutations in genes linked to bile salt and oxidative 
stress response (dinF, yiaH, yciM, sodA, katE, soxS) were tested against manganese 
complex 9.40-43 However, with the exception of YciM, no increased sensitivity compared to 
wildtype E. coli was observed (Fig. 8). Only mutation of the yciM gene led to a significant 
reduction in bacterial growth in the presence of the metal complex, but this effect is fairly 
ubiquitous with antimicrobials.44 Overall, the antibacterial activity of compound 9 does not 
appear to be directly linked to either the presence of the cholate moiety or metal-induced stress 
from oxidation products of the Mn(CO)3 group.45, 46 
 
Figure 8. Growth curves of E. coli single-knockout strains from the Keio collection (red lines) 
compared to wild type BW25113 (black lines) in the presence of 1% DMSO (solid lines) or 
400 µM [Mn(bpencholamide)(CO)3]Br 9 (dashed lines). Points represent the mean OD595 of three 
replicates, and errors bars represent the standard deviation. 
 
Conclusion 
A bis(2-pyridylmethyl)amine (bpa) ligand was conjugated to a cholic acid carrier molecule in 
a simple DCC/NHS-mediated amide coupling on a gram scale. Reaction with manganese(I) or 
rhenium(I) pentacarbonyl bromide gave rise to [M(bpencholamide)(CO)3]Br with M = Mn, Re in 
good yield and purity. The antibacterial activity of these bioconjugates was then explored on 
different bacterial strains with a special focus on methicillin-susceptible (MSSA) vs. 
methicillin-resistant (MRSA) S. aureus and compared to other bpa-type complexes. The two 
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title compounds are potent antibacterial agents for the inhibition of MRSA/MSSA growth in 
vitro with MIC values in the very low micromolar range (2–4 µM). No significant difference 
in potency was observed for the Mn vs. Re complexes. While activity of the rhenium compound 
was not modulated by photoactivation, UV illumination of the manganese complex lead to 
some decrease in activity. Taken together these results strongly indicate that the compounds do 
not act as CO-releasing molecules (CORMs) but rather involve some other mode of activity. 
In the Galleria mellonella larvae model, both compounds were non-toxic at up to 100× MIC 
values, which corresponds to more than 200–300 µM. The manganese compound significantly 
increased the survival of larvae infected with MSSA and MRSA, with 88% survival in the 
treated vs. 46% survival in the non-treated control group. Detailed mechanistic studies were 
carried out on E. coli strains deficient in genes encoding drug efflux pumps as well as 
manganese uptake regulator proteins. Combined with ICP-MS measurements of metal uptake 
in bacterial cells and ATP release measurements, these results indicate that both the Mn and 
Re cholamide complexes are efficiently internalized by E. coli cells, do not interfere with 
membrane integrity, and show increased activity in efflux knockout mutants. Taken together, 
this strongly point to an intracellular mode of action that is not triggered by CO released from 
the metal complexes but rather involves the complete Mn or Re conjugate, or at least a 
significant part of it. As single knockout mutants defective in genes related to bile salt and 
oxidative stress response such as dinF, yiaH, sodA, katE, soxS did not show increased 
sensitivity relative to the wildtype, neither the cholic acid moiety nor the metal-carbonyl 
fragment alone appear to be responsible for the biological activity observed and the search for 
the primary intracellular target continues. Nevertheless, the facile synthesis on a scale of 
several 100 mg, absence of toxicity in G. mellonella at several hundred micromole per liter, 
and very low micromolar antibacterial activity in MSSA/MRSA demonstrate that these 
Mn(bpa)(CO)3 and Re(bpa)(CO)3 cholamide conjugates are interesting candidates for further 





General remarks. All synthetic procedures were performed under anhydrous dinitrogen using 
standard Schlenk and vacuum-line techniques. NMR spectra were recorded on Bruker Avance 
300 (1H: 300.18 MHz, 13C: 75.48 MHz)] and Bruker Avance 500 spectrometers (1H: 500.13 
MHz, 13C: 125.75 MHz) with chemical shifts δ reported in ppm. The residual signal of the 
solvent was used for referencing.47 Signal multiplicities are reported as singlet (s), doublet (d), 
doublet-of-a-doublet (dd), doublet-of-a-doublet-of-a-doublt (ddd), triplet (t), doublet-of-a-
triplet (dt), triplet-of-a-doublet (td), quartet (q) or multiplet (m). Coupling constants J are 
reported in Hz. IR spectra were collected on a Nicolet 380 FT IR spectrometer with a smart 
iFTR accessory on pure solid samples. Signal intensities are reported as very strong (vs), strong 
(s), medium (m), weak (w), or broad (br). ESI mass spectra were recorded on a Thermo Fisher 
Exactive Plus Orbitrap mass spectrometer at a solvent flow rate of 10 µL/min. The CHN 
analysis was done with an Elementar Vario MicroCube instrument. All other chemicals were 
obtained from commerical sources and used as received. 
Synthesis of N-(2-(bis(pyridin-2-ylmethyl)amino)ethyl)cholamide (bpencholamide) (6). 
Cholic acid (1.68 g, 4.11 mmol), N-hydroxysuccinimide (0.52 g, 4.52 mmol) und 
dicyclohexylcarbodiimide (0.93 g, 4.51 mmol) were dissolved in tetrahydrofuran (30 mL) and 
stirred for 24 h at room temperature. The resulting colourless precipitate was filtered off, 
washed with tetrahydrofuran (10 mL), and the solid material discarded. To the colourless 
solution was slowly added N,N-bis(pyridin-2-ylmethyl)ethan-1,2-diamine (1.00 g, 4.13 mmol) 
and N,N-diisopropylethylamine (1.54 mL, 1.17 g, 9.05 mmol). The resulting pale yellow 
solution was stirred at room temperature for 24 h. Then, the solvent was removed under vacuum 
and the residue dissolved in dichlormethane (50 mL). After washing with water (100 mL), 
concentrated aqueous ammonium chloride (50 mL), saturated sodium hydrogen carbonate 
(50 mL), and brine (3 x 50 mL), the yellow organic phase was dried over sodium sulfate and 
then the solvent removed under vacuum. The resulting pale yellow solid was purified by 
column chromatography on silica with a mixture of dichlormethan and methanol (5:1 v/v) as 
the eluent to obtain the product (Rf = 0.45) as a colourless powder. Yield: 71% (1.84 g, 
2.91 mmol). IR (ATR): 𝝂𝝂�  = 3222 (m), 2933 (m), 2862 (w), 1633 (s), 1570 (m), 764 (s) cm-1; 
1H NMR (500.13 MHz, DMSO-d6): δ = 8.47 (ddd, 2H, 3J H6,H5 = 4.9 Hz, 4J H6,H4 = 1.8 Hz, 
5J H6,H3 = 0.9 Hz, py-H6), 7.77 (t, 1H, 3J = 5.8 Hz, CONH), 7.74 (dt, 2H, 3J H4,H5/H3 = 7.7 Hz, 
4J H4,H6 = 1.8 Hz, py-H4), 7.53 (d, 2H, 3J H3,H4 = 7.8 Hz, py-H3), 7.24 (ddd, 2H, 
3J H5,H4 = 7.5 Hz, 3J H5,H6 = 4.9 Hz, 4J H5,H3 = 1.2 Hz, py-H5), 4.32 (d, 1H, 3J OH,CH = 4.4 Hz, 
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cholic acid-C3-OH), 4.10 (d, 1H, 3J OH,CH = 3.6 Hz, cholic acid-C12-OH), 4.01 (d, 1H, 
3J OH,CH = 3.5 Hz, cholic acid-C7-OH), 3.78 (m, 1H, cholic acid-H12), 3.76 (s, 4H, py-CH2), 
3.61 (m, 1H, cholic acid-H7), 3.19 (m, 3H, CH2NHCO+cholic acid-H3), 2.54 (t, 2H, 
3J = 6.6 Hz, (py-CH2)2NCH2), 2.33 – 0.73 (m, 30H, cholic acid-CH3/CH2/CH), 0.56 (s, 3H, 
cholic acid-C18-CH3) ppm; 13C NMR (125.76 MHz, DMSO-d6): δ = 172.43 (CONH), 159.34 
(py-C2), 148.68 (py-C6), 136.41 (py-C4), 122.59 (py-C3), 122.08 (py-C5), 71.00 (cholic acid-
C12), 70.43 (cholic acid-C3), 66.24 (cholic acid-C7), 59.59 (py-CH2), 53.17 ((py-CH2)2NCH2), 
46.09 (cholic acid-C17), 45.71 (cholic acid-C13), 41.52 (cholic acid-C5), 41.38 (cholic acid-
C14), 40.04 (cholic acid-C4, overlapping with solvent peak), 39.95 (cholic acid-C8, 
overlapping with solvent peak), 36.62 (CH2NHCO), 35.31 (cholic acid-C1), 35.15 (cholic acid-
C20), 34.89 (cholic acid-C6), 34.38 (cholic acid-C10), 32.53 (cholic acid-C23), 31.71 (cholic 
acid-C22), 30.40 (cholic acid-C2), 28.57 (cholic acid-C11), 27.29 (cholic acid-C16), 26.22 
(cholic acid-C9), 22.79 (cholic acid-C15), 22.63 (cholic acid-C19), 17.12 (cholic acid-C21), 
12.33 (cholic acid-C18) ppm; MS (ESI+, CH3OH): m/z = 633.4343 [M+H]+, 655.4163 
[M+Na]+,1287.8439 [2M+Na]+; Elemental analysis (%) calcd. for C38H56N4O4 ∙ H2O: C 
70.12, H 8.98, N 8.61; found (%): C 69.67, H 8.97, N 8.79. 
Synthesis of [Mn(bpencholamide-κ3N)(CO)3]Br (9). Manganese pentacarbonyl bromide 
(261 mg, 0.95 mmol) and N-(2-(bis(pyridin-2-ylmethyl)amino)ethyl)cholamide (600 mg, 
0.95 mmol) were dissolved under argon in anhydrous degassed dichlormethane (50 mL) and 
then heated to reflux under protection from light for 3 h. Then, the solvent was removed under 
vacuum and the solid residue washed with diethyl ether (3 x 30 ml). After drying under 
vacuum, the product was obtained as a yellow powder. Yield: 76% (614 mg, 0.72 mmol). IR 
(ATR): 𝝂𝝂�  = 3270 (br), 2937 (w), 2023 (vs), 1914 (vs), 1657 (w), 1611 (w), 1536 (w), 1444 (w), 
769 (w) cm-1;  1H NMR (500.13 MHz, DMSO-d6): δ = 8.87 (d, 2H, 3J H6,H5 = 5.3 Hz, py-H6), 
8.10 (t, 1H, 3J = 5.0 Hz, CONH), 7.91 (t, 2H, 3J H4,H5/H3 = 7.6 Hz, py-H4), 7.43 (m, 4H, py-H3, 
py-H5), 4.88 (d, 2H, 2J = 16.7 Hz, py-CH2), 4.71 (d, 2H, 2J = 17.0 Hz, py-CH2), 4.32 (d, 1H, 
3J OH,CH = 3.8 Hz, cholic acid-C3-OH), 4.10 (d, 1H, 3J OH,CH = 3.3 Hz, cholic acid-C12-OH), 
4.00 (d, 1H, 3J OH,CH = 3.1 Hz, cholic acid-C7-OH), 3.78 (m, 3H, (py-CH2)2NCH2+cholic acid-
H12), 3.61 (m, 3H, CH2NHCO+cholic acid-H7), 3.18 (m, 1H, cholic acid-H12), 2.31 – 0.71 
(m, 30H, cholic acid-CH3/CH2/CH), 0.58 (s, 3H, cholic acid-C18-CH3) ppm; 13C NMR 
(125.76 MHz, DMSO-d6): δ = 218.90 (CO), 218.35 (CO), 173.15 (CONH), 160.26 (py-C2), 
152.09 (py-C6), 139.60 (py-C4), 125.37 (py-C3), 122.50 (py-C5), 70.96 (cholic acid-C12), 
70.37 (cholic acid-C3), 66.85 ((py-CH2)2NCH2), 66.27 (py-CH2), 66.19 (cholic acid -C7), 
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46.11 (cholic acid-C17), 45.68 (cholic acid-C13), 41.46 (cholic acid-C5), 41.37 (cholic acid-
C14), 40.02 (cholic acid-C4, overlapping with solvent peak), 39.94 (cholic acid-C8, 
overlapping with solvent peak), 35.26 (cholic acid-C1), 35.12 (cholic acid-C20), 34.86 (cholic 
acid-C6), 34.40 (CH2NHCO), 34.34 (cholic acid-C10), 32.46 (cholic acid-C23), 31.61 (cholic 
acid-C22), 30.36 (cholic acid-C2), 28.53 (cholic acid-C11), 27.33 (cholic acid-C16), 26.19 
(cholic acid-C9), 22.76 (cholic acid-C15), 22.60 (cholic acid-C19), 17.07 (cholic acid-C21), 
12.25 (cholic acid-C18) ppm; MS (ESI+, CH3OH): m/z = 771.3471 [M-Br]+;  Elemental 
analysis (%) calcd. for C41H56BrMnN4O7 · 2 H2O: C 55.47, H 6.81, N 6.31; found (%): C 
55.67, H 6.77, N 6.68. 
Synthesis of [Re(bpencholamide-κ3N)(CO)3]Br (10). Rhenium pentacarbonyl bromide (320 mg, 
0.79 mmol) and N-(2-(bis(pyridin-2-ylmethyl)-amino)ethyl)cholamide (500 mg, 0.79 mmol) 
were dissolved under argon in anhydrous degassed toluene (20 mL) and then heated to reflux 
for 3 h. After removal of the solvent under vacuum, the residue was dissolved in a mixture of 
dichlormethane, acetone, and ethanol (10:10:1 v/v/v, 52.5 mL) and then precipitated by 
addition of diethyl ether (100 mL). The resulting colourless solid was collected by filtration 
and washed with diethyl ether (20 mL). After drying under vaccum overnight, the product was 
obtained as a colourless solid. Yield: 41% (318 mg, 0.32 mmol). IR (ATR): 𝝂𝝂�  = 3383 (br), 
2930 (m), 2028 (vs), 1902 (vs), 1657 (w), 1611 (w), 1535 (w), 1441 (w), 767 (w) cm-1; 
1H NMR (500.13 MHz, DMSO-d6): δ = 8.80 (d, 2H, 3J H6,H5 = 5.3 Hz, py-H6), 8.10 (t, 1H, 
3J = 5.2 Hz, CONH), 7.99 (dt, 2H, 3J H4,H5/H3 = 8.3 Hz, 4J H4,H6 = 1.4 Hz, py-H4), 7.55 (d, 2H, 
3J H3,H4 = 7.8 Hz, py-H3), 7.40 (t, 2H, 3J H5,H4/H6 = 6.5 Hz, py-H5), 5.04 (d, 2H, 2J = 17.1 Hz, 
py-CH2), 4.95 (d, 2H, 2J = 16.5 Hz, py-CH2), 4.32 (d, 1H, 3J OH,CH = 4.3 Hz, cholic acid-C3-
OH), 4.10 (d, 1H, 3J OH,CH = 3.3 Hz, cholic acid-C12-OH), 4.00 (d, 1H, 3J OH,CH = 3.1 Hz, cholic 
acid-C7-OH), 3.83 (t, 2H, 3J = 7.0 Hz, (py-CH2)2NCH2), 3.78 (m, 1H, cholic acid-H12), 3.60 
(m, 3H, CH2NHCO+cholic acid-H7), 3.19 (m, 1H, cholic acid-H3), 2.28 – 0.74 (m, 30H, cholic 
acid-CH3/CH2/CH), 0.58 (s, 3H, cholic acid-C18-CH3) ppm; 13C NMR (125.76 MHz, DMSO-
d6): δ = 196.38 (CO), 195.16 (CO), 173.19 (CONH), 160.52 (py-C2), 151.78 (py-C6), 140.65 
(py-C4), 125.76 (py-C3), 123.40 (py-C5), 70.99 (cholic acid-C12), 70.40 (cholic acid-C3), 
67.87 ((py-CH2)2NCH2), 66.99 (py-CH2), 66.22 (cholic acid-C7), 46.12 (cholic acid-C17), 
45.71 (cholic acid-C13), 41.49 (cholic acid-C5), 41.40 (cholic acid-C14), 40.03 (cholic acid-
C4, overlapping with solvent peak), 39.94 (cholic acid-C8, overlapping with solvent peak), 
35.29 (cholic acid-C1), 35.15 (cholic acid-C20), 34.89 (cholic acid-C6/C10, two overlapping 
signals), 34.37 (CH2NHCO), 32.46 (cholic acid-C23), 31.63 (cholic acid-C22), 30.39 (cholic 
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acid-C2), 28.56 (cholic acid-C11), 27.36 (cholic acid-C16), 26.22 (cholic acid-C9), 22.79 
(cholic acid-C15), 22.63 (cholic acid-C19), 17.10 (cholic acid-C21), 12.30 (cholic acid-C18) 
ppm; MS (ESI+, CH3OH): m/z = 903.3671 [M-Br]+; Elemental analysis (%) calcd. for 
C41H56BrN4O7Re · 4 H2O: C 46.67, H 6.11, N 5.31; found (%): C 45.86, H 5.99, N 5.60. 
Microbiological methods 
Chemicals, media, bacterial isolates, and larvae. Luria broth base, Mueller-Hinton 2 (MH2) 
cation-adjusted broth and cell culture media/supplements were purchased from Sigma-Aldrich 
(Dorset, UK). MRSA strain NCTC 12493 and MSSA strain NCTC 12981 were purchased from 
Pro-Lab Diagnostics (Wirral, UK). MRSA strain USA300 and MSSA strain SH1000 were from 
the Network for Antimicrobial Resistance in S. aureus (NARSA) collection (Eurofins, VA). 
EC958, a multidrug-resistant clinical isolate of uropathogenic E. coli ST131 was obtained from 
___ [Source still missing → Calum, Robert???] E. coli knockout mutant strains utilised were 
from the Keio collection, and the parent strain BW25113 was used as the wildtype for 
comparison. Acinetobacter baumannii isolates AB184 and AB210 were provided by the Royal 
London Hospital (Whitechapel, UK). Isolates were stored on cryobeads at -80 °C until 
required. Antibiotic susceptibility profiles were determined prior to any further testing. All in 
vivo assays were performed using the Galleria mellonella TruLarv model (Biosystems 
Technology, Exeter, UK). Experimental studies using G. mellonella are not subject to any 
regulation under the Animals Scientific Procedures Act (ASPA) 1986. 
The minimum inhibitory concentration (MIC) of 9 and 10 were determined via microdilution 
assays in MH2 broth versus MRSA and MSSA. Microtitre plates were incubated at 37 °C 
aerobically for 18–20 h, after which MICs were recorded. Kill kinetics of both compounds 
were also determined in MH2 broth versus MRSA and MSSA strains over 24 h. In brief, a 
1/1000 dilution of a 18–20 h bacterial culture, with an approximate CFU/mL of 106, was used 
as the starting inoculum for all strains. To individual cultures, antimicrobials were added at x1 
MIC. Cultures were incubated at 37 °C on an orbital shaker (225 rpm) for 24 h. At fixed time 
intervals of 0, 2, 4, 6, and 24 h post inoculation, 100 μL samples were collected, serially diluted, 
and plated onto MH2 agar. Viable counts were determined after incubation aerobically at 37 
°C for 18–20 h. Growth curves of bacterial strains were determined using a Tecan Sunrise 
microplate reader using 96-well microtiter plates. Overnight cultures were diluted 1/100 into 
fresh MH2 broth and grown aerobically in volumes of 100 µL at 37 °C. UV activation of the 
manganese compound was performed as described previously.30 
The toxicity of 9 and 10 was determined in greater wax moth (Galleria mellonella) larvae at 
concentrations of between 10 and 100 times that required for bacterial inhibition. Via a left 
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proleg, 10 µL injections of complex 9 at 10× and 100× MIC for MSSA NCTC 12981 (31 and 
310 µM in 5% DMSO, respectively) and complex 10 at 10× and 100× MIC for MSSA NCTC 
12981 (34 and 340 µM in 5% DMSO) were administered. Phosphate buffered saline (PBS) and 
MSSA strain NCTC 12981 were used as a negative and positive controls, respectively. Larvae 
were incubated at 37 °C for 96 h aerobically. At 24 h time points, larvae were scored for 
survival (live/dead), where death was classified as an absence of movement in response to 
stimulation. The in vivo efficacy of 9 vs. MSSA and MRSA strains was determined in the 
G. mellonella model of infection as previously described. In brief, overnight cultures (18–20 
h) of each strain were washed with PBS and serially diluted. Then, a 10 µL injection via a left 
proleg was administered to 16 larvae per group, containing an inoculum that would result in 
staggered killing over 96 h. After 15 min, larvae were then injected, via a right proleg, with a 
concentration of 9 dissolved in 5% DMSO, equivalent to 10× of the concentration required for 
bacterial inhibition (0.8–1.07 mg/kg). Larvae were incubated  aerobically at 37 °C for 96 h. 
Every 24 h, larvae were scored for survival as described above. The Mantel-Cox Log rank test 
was performed to test for significant differences in larval survival. 
Bioluminescence-based ATP release assays 
The level of extracellular ATP in bacterial cultures following treatment with compounds was 
determined as previously described using the Molecular Probes ATP Determination Kit 
(Invitrogen) and a Lumat3 LB 9508 Luminometer (Berthold Technologies).21  
Metal content determination by ICP-MS 
Intracellular metal content was determined by inductively coupled plasma mass spectrometry 
(ICP-MS). Bacterial cultures were grown to mid-log phase and harvested via centrifugation 
(10,000 × g at 10 °C for 20 min). Pellets were washed three times in wash buffer (10 mM 
HEPES, 0.5 M sorbitol, 100 μM EDTA, pH 7.5) and then washed once in the buffer without 
the EDTA. Washed pellets were resuspended in 65% nitric acid and left at room temperature 
for a minimum of 48 h. The relative abundance of selected metals was determined using ICP-
MS on a Agilent 4500 instrument in the Department of Chemistry, The University of Sheffield. 
The protein concentration of intact cells from each sample analysed by ICP-MS was 
determined simultaneously using the Lowry method. 
 
 
RNA extraction and gene expression analysis by qRT-PCR 
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RNA extraction and qRT-PCR were conducted as previously described.48 Briefly, RNA was 
extracted from mid-log phase cells with and without treatment with [Mn(bqpa-κ3N)(CO)3]Br 
using the TRIzol Max Bacterial RNA Isolation Kit (Thermo Fisher Scientific) with additional 
DNase treatment using a Turbo DNA-free kit (Ambion). Reverse transcription-quantitative 
PCR (qRT-PCR) was performed using a SensiFAST SYBR Lo-ROX one-step kit (Bioline) in 
96-well optical reaction plates, with each reaction performed in technical triplicate. A standard 
curve for each pair of primers was produced using E. coli genomic DNA, and gene expression 
was calculated relative to the reference gene gyrA. PCR amplification was performed using a 
Stratagene MX3005p thermal cycler (Agilent) and relative gene expression levels were 
calculated using the comparative method described in  the user bulletin 2 of the ABI Prism 700 
sequence detection system. Primer pairs used were designed using Primer3web (Version 4.1): 
acrB: 5’-TAATTTCTTTATCGATCGCC-3’ and 5’-GTCACTGTTAGAGGACATGTA-3’ 
acrD: 5’-TCTTTATTGATCGCCCCATT-3’ and 5’-TATCGAGGCCGGTCATATTT-3’ 
mntP: 5’-ATCACTGCTACTGTTCTTCTTGC-3’ and 5’-TAACATGCCCATTCCCCAGC-3’ 
mntH: 5’-TAGCAGCGGACGGGCG-3’ and 5’-CAAACGACAACCCACAGTAGC-3’ 
gyrA: 5’-GGTACACCGTCGCGTACTTT-3’ and 5’-TACCGATTACGTCACCAACG-3’ 
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